Japan: Noile-Immune Biotech returns to TSE to raise JPY2.8bn

Noile-Immune Biotech, a clinical stage biotechnology company exploring innovative cancer immunotherapy based on CAR-T cell therapy, is looking to raise JPY2.8bn (US$20m) with an IPO on TSE. This is the second time this year that Noile-Immune has approached the market, with an attempt at a deal pulled in March. The firm is offering 3.6m primary…

You must be a HMI Subscriber to view this content.

Subscribe Now »